YOLFTbeta
UniPharma Co., Ltd.

UniPharma Co., Ltd.

6621 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

12.30TWD-0.15 (-1.20%)

Price History

Full chart

Market Stats

Previous Close12.45
Open12.45
Day Range12.05 – 12.50
52-Week Range10.60 – 16.00
Volume61.02K
Market Cap440.21M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.13
Dividend Yield0.00%
Beta-0.22
50-Day Avg11.45
200-Day Avg12.10

About

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was founded in 1998 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jen Chen Ph.D.
  • Employees34
  • HeadquartersNo.17, Lane 171, Taipei, Taiwan, 11494, Taiwan
  • Websitehttps://www.uni-pharma.com

Leadership

  • Mr. Jen Chen Ph.D.Chairman of the Board & Chief Strategy Officer
  • Mr. Yu-Shan Wang Ph.D.General Manager, R&D Director and Director
  • Mr. Yi You LuAssistant Manager (Finance & Accounting Supervisor)

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue154.28M138.63M105.39M128.11M103.22M93.45M88.44M
Growth (%)--10.14%-23.98%+21.56%-19.43%-9.46%-5.36%
Cost of Revenue80.53M69.32M46.06M53.49M52.21M44.75M41.22M
Gross Profit73.75M69.32M59.33M74.62M51.02M48.71M47.22M
Gross Margin47.80%50.00%56.29%58.25%49.42%52.12%53.39%
Operating Expense101.55M89.93M99.55M95.50M78.32M79.53M91.35M
Operating Income-27.80M-20.61M-40.22M-20.88M-27.30M-30.82M-44.13M
Operating Margin-18.02%-14.87%-38.17%-16.30%-26.45%-32.98%-49.89%
EBITDA-19.20M-44.04M-63.52M-1.61M-16.25M-17.71M-33.45M
EBITDA Margin-12.45%-31.77%-60.27%-1.26%-15.75%-18.96%-37.82%
Net Income-25.05M-55.35M-74.41M-6.45M-21.81M-24.82M-40.54M
Net Income Margin-16.23%-39.93%-70.60%-5.03%-21.13%-26.56%-45.84%
R&D34.83M24.86M33.05M26.32M17.83M16.57M22.83M
R&D as % of Total Revenue22.58%17.93%31.36%20.54%17.28%17.73%25.81%
Interest Expense163.00K141.00K99.00K39.00K14.00K108.00K99.00K
Interest Expense % of Total Revenue0.11%0.10%0.09%0.03%0.01%0.12%0.11%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets456.14M415.57M348.18M332.57M350.07M328.98M274.99M
Total Liabilities54.94M36.59M50.61M29.33M37.40M44.22M45.20M
Total Equity401.20M378.98M297.57M303.24M312.67M284.75M229.79M
Cash200.48M74.59M75.95M63.76M68.64M58.67M29.00M
Total Debt22.45M16.82M6.99M3.53M277.00K14.78M-
Net Debt-178.03M-57.76M-68.96M-60.23M-68.37M-43.89M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.24M-17.18M-12.93M-31.65M12.03M-14.32M-36.67M
Investing Cash Flow1.93M31.85M19.80M-1.12M-3.89M8.18M-
Financing Cash Flow-8.13M-5.57M-5.49M20.57M-3.26M-3.83M-
Capital Expenditure283.00K638.00K3.21M435.00K8.11M2.84M1.88M
Free Cash Flow-9.52M-17.82M-16.14M-32.09M3.92M-17.16M-38.55M
FCF to OCF103.06%103.71%124.79%101.37%32.61%119.83%105.12%

Key Statistics & Ratios

Market Cap440.21M
Enterprise Value328.98M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.25
Price / Book2.16
EPS-1.13
Book Value5.54
Revenue (TTM)83.87M
Gross Profit (TTM)42.65M
EBITDA-42.62M
Profit Margin-47.81%
Operating Margin-62.61%
Return on Equity-17.90%
Return on Assets-10.86%
Shares Outstanding35.50M
Shares Float27.15M
Beta-0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%